As of today (2022-05-21), Myovant Sciences's share price is $10.49.
Myovant Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.88. Hence, Myovant Sciences's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Myovant Sciences's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 7 years, Myovant Sciences's highest Price-to-Operating-Cash-Flow Ratio was 6.67. The lowest was 0.00. And the median was 5.07.
Myovant Sciences's Cash Flow from Operations per share for the
three
months ended in Mar. 2022 was $-1.06.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.88.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Myovant Sciences was -170.20% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.80% per year.
During the past 7 years, Myovant Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 4.80% per year. The lowest was -91.00% per year. And the median was -43.10% per year.
Myovant Sciences Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Myovant Sciences's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Myovant Sciences Annual Data
|
|
Trend |
Mar16 |
Mar17 |
Mar18 |
Mar19 |
Mar20 |
Mar21 |
Mar22 |
| Price-to-Operating-Cash-Flow |
|
|
|
- |
- |
- |
5.00 |
- |
|
Myovant Sciences Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00 |
6.37 |
4.97 |
- |
- |
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Price-to-Operating-Cash-Flow Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Price-to-Operating-Cash-Flow falls into.
Myovant Sciences Price-to-Operating-Cash-Flow Calculation
Myovant Sciences's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 10.49 | / | -2.883 |
| = | |
Myovant Sciences's Share Price of today is $10.49.
Myovant Sciences's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Myovant Sciences Business Description
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
| Potter Myrtle S |
director |
10 FINDERNE AVE BRIDGEWATER NJ 08807 |
| Guinan Mark |
director |
C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
| Arjona Ferreira Juan Camilo |
officer: Chief Medical Officer |
C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
| Curran Terrie |
director |
C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
| Gulfo Adele M. |
director |
ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
| Sebelius Kathleen |
director |
C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
| Lang Matthew |
officer: General Counsel & Corp. Secy. |
C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
| Sumitomo Chemical Co., Ltd. |
10 percent owner |
27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
| Sumitovant Biopharma Ltd. |
10 percent owner |
C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
| Dainippon Sumitomo Pharma Co Ltd |
10 percent owner |
60 WALL STREET NEW YORK NY 10005 |
| Seely Lynn |
director, officer: Principal Executive Officer |
501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
| Sablich Kim |
officer: Chief Commercial Officer |
C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
| Nomura Hiroshi |
director |
C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
| Roivant Sciences Ltd. |
10 percent owner |
CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
| Torti Frank |
director |
2855 SAND HILL ROAD MENLO PARK CA 94025 |
Myovant Sciences Headlines
By Seekingalpha 2021-06-02
By Seekingalpha 2021-05-24
By Seekingalpha 2022-01-26
By Seekingalpha 2022-01-02
By Seekingalpha 2021-01-19
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 491,528 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 